Celldex TherapeuticsCLDX
CLDX
About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Employees: 186
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $17.1M
38% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 48
2.75% more ownership
Funds ownership: 108.33% [Q3] → 111.07% (+2.75%) [Q4]
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
1% less funds holding
Funds holding: 176 [Q3] → 174 (-2) [Q4]
24% less capital invested
Capital invested by funds: $2.44B [Q3] → $1.86B (-$579M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
73%
upside
Avg. target
$54
159%
upside
High target
$80
284%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Canaccord Genuity Edward Nash 65% 1-year accuracy 13 / 20 met price target | 207%upside $64 | Buy Initiated | 28 Apr 2025 |
Morgan Stanley Judah Frommer 50% 1-year accuracy 5 / 10 met price target | 121%upside $46 | Overweight Initiated | 20 Mar 2025 |
Goldman Sachs Richard Law 63% 1-year accuracy 5 / 8 met price target | 73%upside $36 | Neutral Maintained | 3 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 284%upside $80 | Buy Reiterated | 3 Mar 2025 |
UBS Trung Huynh 25% 1-year accuracy 2 / 8 met price target | 111%upside $44 | Buy Initiated | 13 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Neutral
GlobeNewsWire
1 month ago
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing -
Neutral
GlobeNewsWire
1 month ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 -
Negative
Zacks Investment Research
2 months ago
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update.
Neutral
GlobeNewsWire
4 months ago
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fundamental processes that characterize AD, including epithelial barrier dysfunction, immune cell recruitment, neuroinflammation2 and multiple other mast cell-associated factors that correlate with disease severity. Activated mast cells are also found in increased numbers in lesional biopsies. Barzolvolimab is a humanized monoclonal antibody that specifically binds and blocks the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell.
Neutral
GlobeNewsWire
5 months ago
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation.
Neutral
GlobeNewsWire
5 months ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Negative
Zacks Investment Research
5 months ago
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
Neutral
GlobeNewsWire
5 months ago
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Charts implemented using Lightweight Charts™